Janssen Inc.'s single-tablet regimen for HIV, Symtuza, is as effective as its component drugs taken in multiple pills in previously untreated patients infected with HIV-1, data from the AMBER study show. The data form part of Janssen's NDA filing for the product made to the US FDA in September.
Symtuza contains darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg (D/C/F/TAF) in one once-daily...